
ARK GROUP RETAINS AFFINITY BIO PARTNERS, AI HEALTH OUTCOMES AND CANNABOT
Affinity Bio Partners, AI Health Outcomes and CannaBot will work together to manage research and development projects, clinical studies, assist with patient education, utilization of artificial technology through the CannaBot™ for ARK’s Research and Development efforts within South Africa as well as ARK’s entrance into the United States market.